Education
About Us
Working with TipRanks
Follow Us
Biofrontera AG (GB:0DOL)
:0DOL
0DOL Stock Chart & Stats
Day’s Range― - ―
52-Week Range€14.30 - €14.30
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€15.07M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)3.67M
Price to Earnings (P/E)541.6
Beta0.00
Next Earnings
Jun 03, 2026EPS EstimateN/A
Last Dividend Ex-Date
Mar 15, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,076,862
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Biofrontera News
PremiumCompany Announcements
Biofrontera Completes Strategic Restructuring Agreement
PremiumCompany Announcements
Biofrontera AG Extends Payment Deferral Amid Strategic NegotiationsPremiumCompany Announcements
Biofrontera AG Extends Payment Deferral Amid Ongoing Negotiations
PremiumCompany Announcements
Biofrontera AG Explores Strategic Changes with Biofrontera Inc.
PremiumCompany Announcements
Biofrontera AG Pre-announces H1 2025 Financial Report
PremiumCompany Announcements
Biofrontera AG’s Q1 2025 Earnings Call Highlights0DOL FAQ
What was Biofrontera AG’s price range in the past 12 months?
Biofrontera AG lowest share price was €14.30 and its highest was €14.30 in the past 12 months.
What is Biofrontera AG’s market cap?
Biofrontera AG’s market cap is €15.07M.
When is Biofrontera AG’s upcoming earnings report date?
Biofrontera AG’s upcoming earnings report date is Jun 03, 2026 which is in 329 days.
How were Biofrontera AG’s earnings last quarter?
Currently, no data Available
Is Biofrontera AG overvalued?
According to Wall Street analysts Biofrontera AG’s price is currently Overvalued.
Does Biofrontera AG pay dividends?
Biofrontera AG pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Biofrontera AG dividends here
What is Biofrontera AG’s EPS estimate?
Biofrontera AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biofrontera AG have?
Biofrontera AG has 6,076,862 shares outstanding.
What happened to Biofrontera AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biofrontera AG?
Currently, no hedge funds are holding shares in GB:0DOL
Biofrontera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-22.41%
Trailing 12-Months
Asset Growth
-3.56%
Trailing 12-Months
Company Description
Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.